<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302002</url>
  </required_header>
  <id_info>
    <org_study_id>INCA113/10</org_study_id>
    <nct_id>NCT01302002</nct_id>
  </id_info>
  <brief_title>The Use of Metformin in Early Breast Cancer Patients Pre-Surgery</brief_title>
  <official_title>The Use of Metformin in Early Breast Cancer Patients Pre-Surgery: A Phase 0 Study Regarding The Biological Effect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancer, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancer, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will test metformin in patients with early breast cancer. Blood and tissue will be
      collected before and after the use of metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will take metformin twice a day for 3 weeks before surgery. The hypothesis is that
      metformin will reduce cell proliferation rates (Ki67) and increase apoptoses (TUNEL)in tumor
      tissue.

      The study will collect and analyze pre- and post-treatment blood specimens for:

        -  Serum glucose

        -  Insulin levels

        -  Estradiol

        -  HOMA test

        -  Glycosylated haemoglobin
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the in situ effects of metformin in women with operable stage I or II breast cancer</measure>
    <time_frame>60 days after the surgery</time_frame>
    <description>To determine the in situ effects of metformin on
proliferation (Ki67) and apoptosis (TUNEL), fosforilate AKT
CD1a CD83, CD68, F40/80, arginase iNOS and T cells -CD4(+),CD45RA(+), CD 45RO, CD4, CD8 and FOXP3(+).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To analyse gastrointestinal toxicity</measure>
    <time_frame>One week , 2 weeks and 20 days after Metformim beginning</time_frame>
    <description>To analyse gastrointestinal toxicity grade (examples: nausea, stomach pain, vomiting)
Number of Participants with Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyse the blood tests one day before the biopsy and one day before the surgery</measure>
    <time_frame>5 days after blood collection</time_frame>
    <description>-To collect and analyze pre- and post-treatment peripheral blood specimens for serum glucose, glycosylated haemoglobin and insulin levels, as well as circulating IGF-1 and estradiol</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Metformin Pre-Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take metformin twice a day for three weeks prior surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Pre-Surgery</intervention_name>
    <description>500 mg tablet, taken twice a day for 3 weeks</description>
    <arm_group_label>Metformin Pre-Surgery</arm_group_label>
    <other_name>Laboratory biomarker analysis</other_name>
    <other_name>Blood and tissue collection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Invasive breast cancer T1 or T2, Nx

          -  Knowledge of the investigational nature of the study and ability to provide consent
             for study participation

        Exclusion Criteria:

          -  Diabetes or baseline glucose or Glycosylated haemoglobin upper limit of normal for the
             institution

          -  Recent use of corticosteroids

          -  AST &gt; 1.5 times upper limit of normal for the institution

          -  Pregnancy

          -  Serious clinical illness

          -  Prior or concurrent systemic neoadjuvant Breast Cancer therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Elisa Lohmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cancer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital do Cancer III</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20560-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancer, Brazil</investigator_affiliation>
    <investigator_full_name>Ana Elisa Lohmann</investigator_full_name>
    <investigator_title>Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Metformin</keyword>
  <keyword>Pre-Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

